SCHEMBL2179260

SCHEMBL2179260

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=S)Nc4cccc(F)c4)cc3)cc2C1=O

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PPIA P62937 1/20 0.46
THRB P10828 2/20 0.44
LMNA P02545 2/20 0.44
DGAT1 O75907 2/20 0.43
TP53 P04637 1/20 0.42
EGFR P00533 2/20 0.42
KDR P35968 2/20 0.41
SDCBP O00560 3/20 0.41
SDC2 P34741 3/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
GAA P10253 2/20 0.40
EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181156 1.00 PPIA (0.46) PPIATHRBLMNADGAT1TP53
SCHEMBL2179511 0.93 DGAT1 (0.47) PPIATHRBLMNADGAT1TP53
SCHEMBL2180663 0.93 DGAT1 (0.47) PPIATHRBLMNADGAT1TP53
SCHEMBL2177864 0.93 KDR (0.49) THRBLMNADGAT1TP53EGFR
SCHEMBL2176748 0.93 KDR (0.49) THRBLMNADGAT1TP53EGFR
SCHEMBL2179028 0.89 SDCBP (0.45) LMNADGAT1TP53KDRSDCBP
SCHEMBL2179086 0.89 THRB (0.46) THRBLMNADGAT1TP53KDR
SCHEMBL2178767 0.89 THRB (0.46) THRBLMNADGAT1TP53KDR
SCHEMBL2180314 0.88 LMNA (0.52) PPIALMNADGAT1TP53KDR
SCHEMBL2180307 0.88 LMNA (0.52) PPIALMNADGAT1TP53KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT PPIA 1568/4885THRB 2612/4885LMNA 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.